Condition: Post Operative Pulmonary Complications · Neuromuscular Blockade · General Anesthesia · Sponsor: The University of Texas Medical Branch, Galveston
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
This description comes directly from the study's public registry record.
Michael Kinsky, MD · 409-772-1011 · mkinsky@utmb.edu
Always discuss trial participation with your own doctor first.
| University of Texas Medical Branch | Galveston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07203287